Press conference regarding Senzime’s successful collaboration with the University of Debrecen

News: Uppsala, March 6, 2019. Senzime AB (publ) today announces that a press conference has been held at the University of Debrecen, Department of Anesthesiology and Intensive Care, focusing on their participation in testing and validating the TetraGraph during the last 5 years.

“Many years of hard work has led us to the great performance TetraGraph displays today, with impressive accuracy and ease of use. The Department of Anesthesiology and Intensive Care at the University of Debrecen has been very important in this iterative process to validate and finetune the TetraGraph, and Professor Bela Fulesdi and Dr Reka Nemes have been key persons in this process”, says Pia Renaudin, CEO at Senzime.

After an initial speech by Professor Sorin Brull to the assembled journalists about the significance of neuromuscular monitoring, Professor Bela Fulesdi gave an historical background to how the cooperation started and its importance to the department. Dr Reka Nemes demonstrated the use of the monitor with the help of a short film and Senzime CEO Pia Renaudin spoke about business prospects of the monitor as well as the planned future cooperation between the two partners. The press conference was concluded with speeches from University of Debrecen’s Vice rector and the Dean.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                                 

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com         

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com